PMID- 23010712
OWN - NLM
STAT- MEDLINE
DCOM- 20121204
LR  - 20211203
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 138
IP  - 4
DP  - 2012 Oct
TI  - Early posttransplant lymphoproliferative disease: clinicopathologic features and 
      correlation with mTOR signaling pathway activation.
PG  - 568-78
AB  - Early posttransplant lymphoproliferative disorders (EPTLDs) represent the first 
      changes in posttransplant lymphoproliferative disorders (PTLDs) morphologic 
      spectrum. EPTLD data are available mostly from case reports and series that 
      include other types of PTLD. Fifteen EPTLDs were reviewed retrospectively. 
      Clinical data, histopathology, clonality, and Epstein- Barr virus (EBV) status 
      were correlated with staining intensity to an antibody for phosphorylated S6 
      (pS6) ribosomal protein, a downstream effector of mammalian target of rapamycin 
      (mTOR). Median time from transplantation to EPTLD was 50 months (range, 7-135 
      mo). EPTLDs involved tonsil and/or adenoids (n = 11) and lymph nodes (n = 4), all 
      of which were nonclonal and EBV-encoded RNA-positive. Most (n = 11) were 
      plasmacytic hyperplasia and florid follicular hyperplasia (n = 4). All regressed 
      with reduced immunosuppression, and had increased pS6 staining compared with 
      normal tonsil (P = .002, F test). EPTLDs developed later than previously 
      reported, involved mostly tonsils/adenoids, were EBV-encoded RNA (EBER) positive, 
      showed increased pS6, and had excellent clinical outcome with reduction of 
      immunosuppression.
FAU - Nelson, Beverly P
AU  - Nelson BP
AD  - Dept of Pathology, Northwestern University Feinberg School of Medicine, 251 East 
      Huron St, Chicago, IL 60611-2908, USA. bpnelson@northwestern.edu
FAU - Wolniak, Kristy L
AU  - Wolniak KL
FAU - Evens, Andrew
AU  - Evens A
FAU - Chenn, Anjen
AU  - Chenn A
FAU - Maddalozzo, John
AU  - Maddalozzo J
FAU - Proytcheva, Maria
AU  - Proytcheva M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (RNA-Binding Proteins)
RN  - 0 (Ribosomal Protein S6)
RN  - 0 (Ribosomal Proteins)
RN  - 135844-68-7 (RPL22 protein, human)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Clone Cells
MH  - Early Diagnosis
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Infant
MH  - Lymphoid Tissue/metabolism/pathology/virology
MH  - Lymphoproliferative Disorders/drug therapy/*etiology/metabolism/*pathology
MH  - Male
MH  - Middle Aged
MH  - Organ Transplantation/*adverse effects
MH  - Phosphorylation
MH  - Postoperative Complications
MH  - RNA-Binding Proteins/metabolism
MH  - Retrospective Studies
MH  - Ribosomal Protein S6/metabolism
MH  - Ribosomal Proteins/metabolism
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/immunology/*metabolism
MH  - Time Factors
MH  - Young Adult
EDAT- 2012/09/27 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/09/27 06:00
PHST- 2012/09/27 06:00 [entrez]
PHST- 2012/09/27 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 138/4/568 [pii]
AID - 10.1309/AJCPQYYE04AVGVYI [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2012 Oct;138(4):568-78. doi: 10.1309/AJCPQYYE04AVGVYI.